Chronic neuroleptic-induced mouth movements in the rat: suppression by CCK and selective dopamine D1 and D2 receptor antagonists

Psychopharmacology

Volumn 98, Issue 3, 1989, Pages 372-379

  Stoessl, A J ^a   Dourish, C T ^a   Iversen, S D ^a  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

Author keywords

CCK; Cholinergic; Dopamine; Dyskinesias; Mouth movements; Neuroleptics

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CHOLECYSTOKININ; DEVAZEPIDE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; FLUPHENAZINE; PHYSOSTIGMINE; RACLOPRIDE; SCOPOLAMINE;

ANIMAL MODEL; BEHAVIOR; CONTROLLED STUDY; DOSE RESPONSE; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUTH; MOVEMENT (PHYSIOLOGY); NONHUMAN; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; TARDIVE DYSKINESIA;

ANIMAL; ANTIPSYCHOTIC AGENTS; BENZAZEPINES; BENZODIAZEPINONES; CHOLECYSTOKININ; DEVAZEPIDE; MALE; MOUTH; PARASYMPATHETIC NERVOUS SYSTEM; PHYSOSTIGMINE; RACLOPRIDE; RATS; RATS, INBRED STRAINS; RECEPTORS, DOPAMINE; SALICYLAMIDES; SCH-23390; SCOPOLAMINE; STEREOTYPED BEHAVIOR; SUPPORT, NON-U.S. GOV'T;

EID: 0024315005     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/BF00451690     Document Type: Article

References (71)

1. Remoxipride, a selective dopamine D2 receptor antagonist, in tardive dyskinesia
2. Relative dopamine D1 and D2 receptor affinity and efficacy determine whether dopamine agonists induce hyperactivity or oral stereotypy in rats
3. Pharmacological modification of experimental tardive dyskinesia
4. Neuropeptide modulation of apomorphine-induced stereotyped behaviour
5. SCH 23390 may alter dopamine-mediated motor behaviour via striatal D-1 receptors
6. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain
7. Dopamine, acetylcholine, and GABA effects in acute dystonia in primates
8. Biochemical and pharmacological characterization of an extremely potent and selective non-peptide cholecystokinin antagonist
9. Increase in brain 125I-cholecystokinin (CCK) receptor binding following chronic haloperidol treatment, intracisternal 6-hydroxydopamine or ventral tegmental lesions
10. Changes in dopamine-mediated behaviour during one year's neuroleptic administration
11. Behavioural and neurophysiological evidence for a facilitatory interaction between co-existing transmitters: cholecystokinin and dopamine
12. Selective D-1 dopamine receptor increase following chronic treatment with SCH 23390
13. Choline in tardive dyskinesia and Huntington's disease
14. Chronic neuroleptics alter the effects of the D1 agonist SK&F 38393 and the D2 agonist LY171555 on oral movements in rats
15. Reductions in cholecystokinin-like immunoreactivity in the basal ganglia in Huntington's disease
16. Cholinergic suppression of tardive dyskinesia
17. Neurobiological substrates of tardive dyskinesia: the GABA hypothesis
18. Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-1 receptors
19. Cholecystokinn octapeptide levels in rat brain are changed after subchronic neuroleptic treatment
20. Dopaminergic agents affect neuronal transmission of cholecystokinin in the rat brain
21. The chronic administration of dopamine antagonists and methamphetamine changed the [3H]-cholecystokinin-8 binding sites in the rat frontal cortex
22. Cholecystokinin peptides produce marked reduction of dopamine turnover in discrete areas in the rat brain following intraventricular injection
23. Choline and lecithin in the treatment of tardive dyskinesia: preliminary results from a pilot study
24. Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia
25. Effects of acetylcholine agonists and antagonists on yawning and analgesia in the rat
26. Haloperidol-induced tardive dyskinesia in monkeys
27. Oral dyskinesia in rats following brain lesions and neuroleptic drug administration
28. Spontaneous chewing movements in rats during acute and chronic antipsychotic drug administration
29. Localization of cholecystokinin receptors to neuronal elements in the rat caudate nucleus
30. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective dopamine receptor upregulation
31. Cholecystokinin-like peptides potentiate apomorphine-induced inhibition of dopamine neurons
32. Behavioral consequences of long-term treatment with neuroleptic drugs
33. Neuroleptics and tardive dyskinesia
34. Chronic pharmacological manipulation of dopamine receptors in brain
35. Opposite effects of a D1 and D2 agonist on oral movements in rats
36. Tardive dyskinesia: prevalence and risk factors, 1959–1979
37. Behavioral evidence for the involvement of endogenous opioids in the interaction between cholecystokinin and brain dopamine systems
38. Effect of cholinergic and anticholinergic agents on tardive dyskinesia
39. Monkey model of tardive dyskinesia (TD): evidence that reversible TD may turn into irreversible TD
40. In vivo electrochemical analysis of cholecystokinin-induced inhibition of dopamine release in the nucleus accumbens
41. Neuroleptic-induced oral movements in rats: methodological issues
42. Permissive role of D-1 receptor stimulation for the expression of D-2 mediated behavioral responses: a quantitative phenomenological study in rats
43. Effect of cholecystokin-octapeptide on dopamine release from slices of cat caudate nucleus
44. Locomotor behaviors in response to new selective D-1 and D-2 dopamine receptor agonists, and the influence of selective antagonists
45. Dystonic reaction possibly induced by cholinesterase inhibitor insecticides
46. A behavioral pharmacological study on CCK-8 related peptides in mice
47. Effect of Ceruletide on tardive dyskinesia: a pilot study of quantitative computer analyses on electromyogram and microvibration
48. Effect of a cholinomimetic drug (RS86) in tardive dyskinesia and drug-related parkinsonism
49. The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions
50. Effects of the putative D-1 antagonist SCH 23390 on stereotyped behaviour induced by the D-2 agonist RU24213
51. Induction of oral dyskinesias in naive rats by D1 stimulation
52. Selective dopamine D2 receptor reduction enhances a D1 mediated oral dyskinesia in rats
53. Cholinergic manipulation of perioral behaviour induced by chronic neuroleptic administration to rats
54. Acute dystonia induced by neuroleptic drugs
55. Behavioural and pharmacological characterization of the mouth movements induced by muscarinic agonists in the rat
56. Acute dystonic reaction to bethanecol—a direct acetylcholine receptor agonist
57. The neuropharmacology of tardive dyskinesia, spontaneous dyskinesia, and other dystonias
58. Pharmacologically induced behavioural supersensitivity to apomorphine
59. Physostigmine in choreiform movement disorders
60. Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine and electroconvulsive therapy
61. Is yawning a cholinergic response?
62. Enhanced stereotyped response to apomorphine after chronic D-1 blockade with SCH 23390
63. In vivo release of dopamine in the nucleus accumbens of the rat: modulation by cholecystokinin
64. Prolonged dopamine receptor blockade in rats after termination of long-term depot fluphenazine
65. The status of late-onset vacuous chewing/perioral movements during long-term neuroleptic treatment in rodents: tardive dyskinesia or dystonia?
66. Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment
67. A reappraisal of abnormal, involuntary movements (tardive dyskinesia) in schizophrenia and other disorders: animal models and alternative hypotheses
68. D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects
69. Does cholecystokinin potentiate dopamine action in the nucleus accumbens?
70. D-1 dopamine receptor stimulation enables the inhibition of nucleus accumbens neurons by a D-2 receptor agonist
71. Antistereotypic effects of cholecystokinin octapeptide (CCK-8), ceruletide and related peptides on apomorphine-induced grawing in sensitized mice